Status:
COMPLETED
Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients
Eligibility Criteria
Inclusion
- Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10%
- Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL
- BMI ≤ 40 kg/m2
Exclusion
- Active tuberculosis
- Symptoms of poorly controlled diabetes
- History of diabetic ketoacidosis
- Significant cardiovascular history or gastrointestinal disorders
- History of unstable or rapidly progressing renal disease
- Active liver disease and/or significant abnormal liver function
- Abnormal chest x-ray at screening indicative of tuberculosis or other infection
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00699790
Start Date
February 1 2009
End Date
December 1 2009
Last Update
October 12 2015
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Dzerzhnsky, Russia, 140090
2
Local Institution
Moscow, Russia, 105229
3
Local Institution
Moscow, Russia, 117036
4
Local Institution
Moscow, Russia, 125315